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The JID Opens Its Doors to High-Quality 
Randomized Controlled Clinical Trials
The Journal of Investigative Dermatology (JID) may not strike you as the most obvi-ous place to submit the results of your 
randomized controlled clinical trial (RCT) for 
publication. Over the last 6 years, for instance, 
the JID has published only 13 full RCTs 
compared with 151 in the British Journal of 
Dermatology (Table 1). Such a paucity of RCTs 
in the JID is largely due to a low number of sub-
missions — possibly fuelled by the misguided 
perception that the JID is only concerned with 
basic science. People just do not think of the JID 
when considering where to publish their trial.
But things are about to change. Over the 
past few years, the JID has strived to increase its 
clinical relevance and scope of publications by 
including high-quality studies on epidemiology, 
health-services research, and clinical dermatol ogy. 
The interest in clinical trials in the JID has exist-
ed from our very inception in 1938. The second 
issue of this journal reported an extensive study 
of the effect of a gold compound, ammonium 
succinimido-aurate, in 86 patients with lupus 
erythematosus (Obermayer and Becker, 1938). 
Perceptive presidential addresses by Donald 
Pillsbury on controls in clinical investigations 
(Pillsbury et al., 1950) and Harvey Blank on 
bringing science to clinical trials (Blank, 1961) 
addressed many issues still relevant today. These 
two papers gathering dust in papyro-space are 
appended, allowing easy review of the prescient 
remarks of these individuals (see Supplementary 
Articles S1 and S2). We realize that the RCT is the 
current gold standard, but one should not be sur-
prised when it is superseded and replaced by new 
ways of clinical study and analysis. Because many 
of those reading the JID today are practicing clini-
cians with an interest in evidence-based dermato-
logy who wish to base their treatment choices on 
reliable evidence from randomized controlled tri-
als, the JID wishes to actively encourage trialists to 
submit their findings to the journal. With its high 
impact factor and wide circulation through Nature 
Publishing Group, publishing a clinical trial in the 
JID means that it will reach a wide and influential 
audience. So, now that we have declared an inter-
est in publishing RCTs, the question arises: what 
sort of trials? The short answer is that we would 
like the good ones — trials that are both important 
and well reported. These terms require elaboration 
in order to guide potential authors.
By “important” we mean trials that could 
have a significant impact for clinicians and their 
patients. Non-pharmacological interventions can 
be particularly interesting (Staab et al., 2006), 
and trials of existing treatments that have never 
been tested in RCTs can also be worthwhile 
(Heydendael et al., 2003). Trials that reveal novel 
insights into disease mechanisms and industry-
independent studies that compare new pharma-
cological agents against existing active therapies 
are also encouraged (Wolkenstein et al., 1998; 
Ozolins et al., 2004). We are less interested in tri-
als that investigate small incremental differences 
in “me too” drugs, dose-finding studies, and tri-
als of new pharmacological agents that compare 
their drugs against placebo only. By “well report-
ed,” we mean that the trial must include the sort 
of essential data that will allow a reader to quick-
ly appraise the quality of the study. Like other 
top journals, the JID has adopted the CONSORT 
statement (www.consort-statement.org) in its 
instructions to authors to ensure that all the essen-
tial components of the trial are described (Moher 
et al., 2001). Yet another checklist might sound a 
little tedious for those submitting papers, but the 
general standard of reporting clinical trials in der-
matology has not been good in the past (Adetugbo 
and Williams, 2000). Information such as a parti-
cipant flow diagram indicating how many partici-
pants were initially randomized and how many 
were eventually accounted for in the analysis is 
considered essential in order to understand how 
the conclusions of a trial relate to those who took 
part in it (Egger et al., 2001). A clear description of 
how the randomization sequence was generated 
and subsequently concealed from those recruit-
ing study participants has been shown to be a key 
indicator of study quality (Hewitt et al., 2005), yet 
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such information is frequently completely missing from derma-
tology trial reports (Hoare et al., 2000). The same is true of the 
description of procedures for blinding those who assess study 
outcomes, and whether all those randomized were included in 
the final analysis (intention-to-treat analysis). Just as you would 
not buy a car without seeing its service-history documentation, 
we will not buy your trial unless the report includes vital infor-
mation on how the study was done. Studies that try to improve 
RCT methodology are of interest as well. Studies that are not 
strictly RCTs but that form part of clinical trials with unique 
physiologically based therapies, such as the decrease of skin 
capillary globotriaosylceramide during treatment with recom-
binant α-galactosidase A, are always of interest to our readers 
(Thurberg et al., 2004).
As the JID announced last year (Williams and Stern, 
2005), it has now also adopted the International Committee 
of Medical Journal Editors policy for all of its trials to have 
been registered in an approved publicly accessible clinical-
trials register such as the National Institutes of Health regis-
ter (www.clinicaltrials.gov), the Current Controlled Trials 
register (http://www.controlled-trials.com/), or the Cochrane 
Skin Group register, which is unique to dermatology trials 
(http://www.nottingham.ac.uk/ongoingskintrials/). All trials 
that started enrolling participants after 1 July 2005 must have 
been registered before that date in order to be considered for 
publication in the JID. Trials that started enrollment before 
1 July 2005 must have been registered before 13 September 
2005 in order to be considered for publication (De Angelis et 
al., 2004). This requirement is an attempt to crack down on 
the distorting effects of publication bias. Selective reporting 
distorts the true effects of medical interventions, leading to 
wastage of doctors’ and patients’ time and public money and 
possibly to serious harm (Chalmers, 2004).
It may sound a little odd for us to demand such require-
ments at a time when we are encouraging new trial submis-
sions, but these are the standards by which the JID will work, 
and our standards are high. Trial reports accepted by the JID 
are assured of widespread and effective dissemination in the 
highest-impact-factor dermatology specialist journal, and read-
ers will have some reassurance that those published meet mini-
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Table 1 | Number of full randomized controlled trial reports in four leading dermatology journals from 2000 to 
2005, identifi ed by hand-searching
Journal 2000 2001 2002 2003 2004 2005 Total
Arch Dermatol 9 8 15 17 20 14 83
Br J Dermatol 23 27 29 21 26 25 151
J Am Acad Dermatol 19 17 21 17 18 15 107
J Invest Dermatol 1 4 2 4 2 0 13
Data kindly provided by Dr. Finola Delamere, Trials Search Co-ordinator of the Cochrane Skin Group.
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